LISATA THERAPEUTICS INC (LSTA) Stock Price & Overview

NASDAQ:LSTAUS1280583022

Current stock price

5.04 USD
+0.01 (+0.2%)
Last:

The current stock price of LSTA is 5.04 USD. Today LSTA is up by 0.2%. In the past month the price increased by 10.28%. In the past year, price increased by 111.77%.

LSTA Key Statistics

52-Week Range1.81 - 5.07
Current LSTA stock price positioned within its 52-week range.
1-Month Range4.03 - 5.07
Current LSTA stock price positioned within its 1-month range.
Market Cap
44.453M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-2.13
Dividend Yield
N/A

LSTA Stock Performance

Today
+0.2%
1 Week
N/A
1 Month
+10.28%
3 Months
+144.66%
Longer-term
6 Months +116.31%
1 Year +111.77%
2 Years +61.54%
3 Years +55.32%
5 Years N/A
10 Years N/A

LSTA Stock Chart

LISATA THERAPEUTICS INC / LSTA Daily stock chart

LSTA Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to LSTA. When comparing the yearly performance of all stocks, LSTA is one of the better performing stocks in the market, outperforming 97.97% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LSTA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LSTA. The financial health of LSTA is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LSTA Earnings

Next Earnings DateMay 6, 2026
Last Earnings DateFeb 26, 2026
PeriodQ3 / 2025
EPS Reported-$0.49
Revenue Reported
EPS Surprise 10.21%
Revenue Surprise %

LSTA Forecast & Estimates

9 analysts have analysed LSTA and the average price target is 11.56 USD. This implies a price increase of 129.37% is expected in the next year compared to the current price of 5.04.


Analysts
Analysts82.22
Price Target11.56 (129.37%)
EPS Next Y1.19%
Revenue Next YearN/A

LSTA Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

LSTA Financial Highlights

Over the last trailing twelve months LSTA reported a non-GAAP Earnings per Share(EPS) of -2.13. The EPS increased by 15.14% compared to the year before.


Income Statements
Revenue(TTM)1.07M
Net Income(TTM)-18.24M
Industry RankSector Rank
PM (TTM) N/A
ROA -83.84%
ROE -105%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%16.95%
Sales Q2Q%N/A
EPS 1Y (TTM)15.14%
Revenue 1Y (TTM)N/A

LSTA Ownership

Ownership
Inst Owners8.05%
Shares8.82M
Float6.86M
Ins Owners9.73%
Short Float %0.22%
Short Ratio0.08

LSTA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC14.92388.432B
AMGN AMGEN INC16.05197.413B
GILD GILEAD SCIENCES INC16.43179.993B
VRTX VERTEX PHARMACEUTICALS INC24.04119.226B
REGN REGENERON PHARMACEUTICALS16.1978.843B
ALNY ALNYLAM PHARMACEUTICALS INC42.7441.564B
INSM INSMED INC N/A30.069B
BIIB BIOGEN INC11.426.644B
NTRA NATERA INC N/A26.624B
UTHR UNITED THERAPEUTICS CORP17.8923.498B
MRNA MODERNA INC N/A20.758B
EXAS EXACT SCIENCES CORP341.6619.77B
RVMD REVOLUTION MEDICINES INC N/A18.798B

About LSTA

Company Profile

LSTA logo image Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 26 full-time employees. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.

Company Info

IPO: 1995-11-03

LISATA THERAPEUTICS INC

110 Allen Road, Second Floor

Basking Ridge NEW JERSEY US

Employees: 26

LSTA Company Website

LSTA Investor Relations

Phone: 19082292590

LISATA THERAPEUTICS INC / LSTA FAQ

What does LISATA THERAPEUTICS INC do?

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 26 full-time employees. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.


What is the current price of LSTA stock?

The current stock price of LSTA is 5.04 USD. The price increased by 0.2% in the last trading session.


Does LISATA THERAPEUTICS INC pay dividends?

LSTA does not pay a dividend.


What is the ChartMill technical and fundamental rating of LSTA stock?

LSTA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


On which exchange is LSTA stock listed?

LSTA stock is listed on the Nasdaq exchange.


Can you provide the market cap for LISATA THERAPEUTICS INC?

LISATA THERAPEUTICS INC (LSTA) has a market capitalization of 44.45M USD. This makes LSTA a Nano Cap stock.


What is the outstanding short interest for LISATA THERAPEUTICS INC?

The outstanding short interest for LISATA THERAPEUTICS INC (LSTA) is 0.22% of its float.